Summary

US Attention Deficit Hyperactivity Disorder Market is valued approximately USD 3.19 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.15% over the forecast period 2024-2032. Attention Deficit Hyperactivity Disorder is a neurodevelopmental disorder that frequently appears in childhood and often persists into adult. It is characterized by chronic patterns of inattention, hyperactivity, and impulsivity that impair functioning or development. The key trend of US Attention Deficit Hyperactivity Disorder Market is growing development of novel treatments. Pharmaceutical companies are investing in research and development to introduce new medications and therapies for ADHD. These include formulations with extended-release mechanisms, novel delivery systems, and non-pharmacological interventions like digital therapeutics.

Moreover, growing awareness about ADHD among both healthcare professionals and the general public leads to earlier detection and intervention. Increased understanding of ADHD symptoms and their impact on daily functioning prompts more individuals to seek diagnosis and treatment, thereby driving market growth. Also, improvements in diagnostic tools and techniques, including psychological assessments and neuroimaging technologies, aid in more accurate and timely diagnosis of ADHD. As diagnosis becomes more precise, the market for ADHD-related products and services expands. Additionally, the presence of a robust healthcare infrastructure, including specialized clinics, mental health facilities, and educational institutions, supports the diagnosis and treatment of ADHD. Access to these resources facilitates timely intervention and contributes to the growth of the US Attention Deficit Hyperactivity Disorder Market . However, the side effects and safety concerns are expected to hinder the market growth during the forecast period 2024-2032.

Major market player included in this report are:
Pfizer Inc.
Johnson & Johnson Services Inc.
NEOS Therapeutics Inc.
Supernus Pharmaceutical, Inc.
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:

By Drug Type
Stimulants
Non-stimulants

By Demographics
Children
Adults

By Distribution Channel
Retail Pharmacy
Hospital Pharmacy

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. US Attention Deficit Hyperactivity Disorder Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. US Attention Deficit Hyperactivity Disorder Market Size & Forecast (2022- 2032)
2.2. Segmental Summary
2.2.1. By Drug Type
2.2.2. By Demographics
2.2.3. By Distribution Channel
2.3. Key Trends
2.4. Recession Impact
2.5. Analyst Recommendation & Conclusion
Chapter 3. US Attention Deficit Hyperactivity Disorder Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. US Attention Deficit Hyperactivity Disorder Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. US Attention Deficit Hyperactivity Disorder Market Size & Forecasts by Drug Type 2022-2032
5.1. Stimulants
5.2. Non-stimulants
Chapter 6. US Attention Deficit Hyperactivity Disorder Market Size & Forecasts by Demographics 2022-2032
6.1. Children
6.2. Adults
Chapter 7. US Attention Deficit Hyperactivity Disorder Market Size & Forecasts by Distribution Channel 2022-2032
7.1. Retail Pharmacy
7.2. Hospital Pharmacy
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.1.1. Company 1
8.1.2. Company 2
8.1.3. Company 3
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Pfizer Inc.
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Johnson & Johnson Services Inc.
8.3.3. NEOS Therapeutics Inc.
8.3.4. Supernus Pharmaceutical, Inc.
8.3.5. Company 5
8.3.6. Company 6
8.3.7. Company 7
8.3.8. Company 8
8.3.9. Company 9
8.3.10. Company 10
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes